Evidence map›Paper›PMID 31455252›Full record

ArticleBMC cancer2019

Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer.

K M Islam, T Anggondowati, P E Deviany, J E Ryan, A Fetrick, D Bagenda, M S Copur, A Tolentino, I Vaziri, H A McKean and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Anti-cancer agents in medicinal chemistry · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

K M IslamMedical College of Augusta, Augusta University, 1120 15th Street, CJ 2326, Augusta, GA, 30912, USA. kislam@augusta.edu.
T AnggondowatiDepartment of Epidemiology, University of Nebraska Medical Center College of Public Health, Omaha, NE, USA.
P E DevianyDepartment of Epidemiology, University of Nebraska Medical Center College of Public Health, Omaha, NE, USA.
J E RyanNebraska Cancer Coalition, Lincoln, NE, USA.
A FetrickDepartment of Health Services Research and Administration, University of Nebraska Medical Center College of Public Health, Omaha, NE, USA.
D BagendaDepartment of Anesthesiology, University of Nebraska Medical Center College of Medicine, Omaha, NE, USA.
M S CopurMarry Lanning Healthcare System, Hastings, NE, USA.
A TolentinoAvera Cancer Institute, Sioux Falls, SD, USA.
I VaziriCallahan Cancer Center, North Platte, NE, USA.
H A McKeanAvera Cancer Institute, Sioux Falls, SD, USA.
S DunderSoutheast Nebraska Cancer Center, Lincoln, NE, USA.
J E GrayH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
C HuangDepartment of Veterans Affairs Medical Center, Kansas City, MO, USA.
A K GantiVeterans Administration Health Care Systems Medical Center, Omaha, NE, USA.

Funding

Patient-Centered Outcomes Research Institute CE-12-11-4351
6 · The paper itself

Abstract

backgroundIn the U.S., lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Since no cure exists for advanced lung cancer, the main treatment goal is to prolong survival. Chemotherapy regimens produce side effects with different profiles. Coupling this with individual patient's preferred side effects could result in patient-centered choices leading to better treatment outcomes. There are apparently no previous studies of or tools for assessing and utilizing patient chemotherapy preferences in clinical settings. The long-term goal of the study was to facilitate patients' treatment choices for advanced-stage lung cancer. A primary aim was to determine how preferences for chemotherapy side effects relate to chemotherapy choices.

methodsAn observational, longitudinal, open cohort study of patients with advanced-stage non-small cell lung cancer (NSCLC) was conducted. Data sources included patient medical records and from one to three interviews per subject. Data were analyzed using Chi-square, Fisher's Exact and McNamara's test, and logistic regression.

resultsPatients identified the top three chemotherapy side effects that they would most like to avoid: shortness of breath, bleeding, and fatigue. These side effects were similar between first and last interviews, although the rank order changed after patients experienced chemotherapy.

conclusionsPatients ranked drug side effects that they would most like to avoid. Patient-centered clinical care and patient-centered outcomes research are feasible and may be enhanced by stakeholder commitment. The study results are limited to patients with advanced NSCLC. Most of the subjects were White, since patients were drawn from the U.S. Midwest, a predominantly White population.

Indexed as

Patient PreferenceAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDrug-Related Side Effects and Adverse ReactionsFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingSocioeconomic Factors

Identifiers

PMID31455252
PMCPMC6712837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.